Shares Of Sarepta Tank 50% Ahead Of FDA Panel Advisory Meeting
January 16, 2016 at 15:45 PM EST
On Friday Shares of Sarepta Therapeutics (SRPT) tanked 50% after the FDA published a negative clinical review of the drug. The negative report was released as a preliminary review for what the FDA believes in advance of a Jan. 22 advisory panel.
